Preface
Anna Falanga, Benjamin Brenner, Frederick R. Rickles
Session I
Epidemiology and Pathogenesis of Thrombosis in Cancer
The scale of the
problem
Prins MH
Occult cancer and
idiopathic venous thromboembolism
Piccioli A, Prandoni P
Tissue factor-bearing
microparticles and cancer-associated thrombosis
Furie B, Zwicker J, LaRocca T , Kos C, Bauer B, Furie BC
Blood-borne tissue
factor
Key NS
Tissue factor pathway
inhibitor and cancer
Gruel Y , Tollin J , Regina S , Iochmann S, Hube F, Reverdiau
P
Session II
Experimental models of clotting/tumor interaction
Tissue factor-PAR2
signaling crosstalk in cancer and angiogenesis
Ruf W
Oncogenic events
regulating tissue factor expression
Yu JY, May L, Lhotak V, Milsom C, Li Y, Shahrzad S, Shirasawa S,
Weitz JI, Coomber BL, Micelef J, Guha A,
Klement P, Mackman N, Rak JW
Hemostatic factors support metastasis by impeding
NK cell-mediated elimination of embolic tumor
cells
Degen JL, Massari JV, Talmage KE, La Jeunesse CM, Kombrinck KW,
Flick MJ, Palumbo JS
The met oncogene drives a
genetic program Linking cancer to haemostasis
Boccaccio C, Comoglio PM
Cytokine GRO-a is pivotal
in thrombin-induced angiogenesis
Karpatkin S
Session III
Antithrombotics and fibrinolytics in cancer survival
Low molecular weight
heparin and survival in cancer
Kakkar AK
Fibrinolytics, enzyme
inhibitors, and cancer survival
Schmitt M, Magdolen V, Mengele K, Reuning U, Foekens J, Diamandis
EP, Harbeck N
Vitamin k, warfarin and
prothrombin: an alternate pathway to improve cancer
survival
Liebman HA
Future perspective of
clinical trials of antithrombotics and cancer
survival
Er O
Session IV
Endothelium targeting and anticancer therapies
Clinical trials with
angiogenesis inhibitors
Giaccone G, van Cruijsen H
Vascular complications of
endothelium targeting therapies
Rodeghiero F, Elice F
Commentary on thrombotic
and bleeding complications of clinical trials of growth factor
inhibitors
Kessler CM
Lymphangiogenesis: a new
paradigm for cancer progression and therapy
Alitalo K
Session V
Bleeding and inflammation
Hemorrhage and thrombosis
in acute leukemia
Barbui T, Falanga A
Prevention of
disseminated intravascular coagulation in cancer
Levi M
Bleeding and thrombosis
in childhood cancer
Nowak-Göttl U
The protein C system in
inflammation and cancer: a critical role for
thrombomodulin
Spronk H, Ten Cate H
Session VI
Glycosaminoglycans, cancer and thrombosis
Heparin effects in
metastasis and Trousseau's syndrome: anticoagulation is not the
primary mechanism
Stevenson JL, Choi SH, Wahrenbrock M, Varki A, Varki NM
The impact of heparanase
on cancer progression
Vlodavsky I, Ilan N, Abboud-Jarrous G, Nadir Y, Brenner B, Naggi A,
Pisano C, Casu B
Inhibition of tumor
growth by heparins in vivo
Mousa SA
Session VII
Recent advances on prevention and treatment of venous
thromboembolism in cancer
Clinical outcomes in
cancer patients with concurrent venous thromboembolism: findings
from the RIETE registry
Monreal M , Falgá C , Vilaseca B, Suárez C, Gabriel F,
Carles Tolosa C, Montes J
Unresolved problems in
venous thromboembolism treatment in cancer
Agnelli A, Verso M
The role of new
antithrombotics
Büller HR
Abstracts
Oral
Communications
Antithrombotics and Fibrinolytics in Cancer Survival
Endothelium Targeting and Anticancer Therapies
Bleeding and Inflammation
Glycosaminoglycans, Cancer and Thrombosis
Recent Advances on Prevention and Treatment of VTE in
Cancer
Hypercoagulability
Platelet and Proteolytic Enzymes
Epidemiology of Thrombosis
Management of Thrombosis/Bleeding and Systemic Syndromes
Procoagulant Factors of Tumor Cells and Endothelium
Antithrombotics and Cancer